The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort.
Judy-Anne W. Chapman
No relevant relationships to disclose
Shuzhen Liu
Research Funding - NanoString Technologies
Samuel Leung
No relevant relationships to disclose
Torsten O. Nielsen
Consultant or Advisory Role - Bioclassifier; NanoString Technologies
Stock Ownership - Bioclassifier
Research Funding - NanoString Technologies
Other Remuneration - NanoString Technologies